Perception of Risk through Phases of Drug Research and Development: Questionnaire Survey

被引:0
作者
Ivor Cowlrick
Roland Wolf
Thomas Hedner
Michael Olausson
机构
[1] Astellas Pharma Europe Ltd,Medical Affairs
[2] Göteborg University,Department for Clinical Trials and Entrepreneurship
[3] Sahlgrenska University Hospital at the Sahlgrenska Academy,Department of Surgery and Transplantation
来源
Drug information journal : DIJ / Drug Information Association | 2009年 / 43卷 / 5期
关键词
Risk perception; Research and development; Benefit versus risk; Questionnaire survey; Health professionals;
D O I
暂无
中图分类号
学科分类号
摘要
We used a web-based questionnaire survey to investigate how employees from the pharmaceutical and allied health industries perceive the importance of different steps within drug research and development for assessing the benefits and risks of developmental drugs to reach market registration and enter into clinical use. Key outcomes were that Pharmaceutical Processes were seen as least important while Toxicology was most important followed by Clinical Trials Phases 2 Late/3, Safety and Pharmacovigilance, and Clinical Trials Phase 2 Early. Nonparametric analysis showed that these outcomes were influenced by demographics of the selected employee target population. Since this survey was exploratory, we feel the expressed judgments of the study population are important for planning research surveys using more complex scenarios to investigate intuitive perception of risks and benefits in drug research and development.
引用
收藏
页码:617 / 622
页数:5
相关论文
共 19 条
  • [1] Schuster D(2005)Why drugs fail—a study on side effects in new chemical entities Curr Pharm Design 11 3545-3559
  • [2] Laggner C(2003)Impediments to drug development Wound Repair Regeneration 11 161-165
  • [3] Langer T(2007)A comparison of the drug review process at five internationally regulatory agencies Drug Inf J. 41 291-308
  • [4] Robson M(2007)The probability of registrational success Drug Inf J. 41 345-347
  • [5] Hirako M(2006)Surveying free and low-cost survey software J Natl Med Assoc. 98 881-886
  • [6] McAuslane N(2007)Risk perception of prescription drugs: results of a national survey Drug Inf J. 41 81-100
  • [7] Salek S(2006)Issues facing development of new innovative medicines Drug Inf J. 40 281-289
  • [8] Maniglia CA(1990)Chaput de Saintonge M, Joyce CRB. Clinical judgement analysis Q J Med. 76 935-949
  • [9] Carter-Pokras O(2001)Fast and frugal versus regression models of human judgement Thinking Reasoning 7 5-27
  • [10] McClellan L(undefined)undefined undefined undefined undefined-undefined